의료기기 이야기

[Emergo, UL] US FDA Warning Letters: Considerations for LDTs including Timelines

Importance of reviewing warning lettersBy reviewing relevant U.S. Food and Drug Administration (FDA) warning letters, manufacturers can better understand areas of frequent concern related to quality management systems (QMS) and regulatory affairs. This can allow companies to focus on areas of highest risk as they continually assess and improve their internal procedures and processes. It also hel..

1. Foreword This guidance, relating to the application of Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) addresses the classification of in vitro diagnostic medical devices (IVDs) and provides clarifications on the classification rules as set out under Annex VIII. This classification guidance also applies to diagnostic or information society services performed on EU patie..

Legislative background on shortagesOn March 2, 2022, amendments to the legislation in Canada, Medical Devices Regulations (SOR/98-282, Part 1, Sections 62.21 to 62.26) came into force. These provisions discuss the notification of shortages to the regulator Health Canada. If an explicit device is delineated on the “List of Medical Devices- Notification of Shortages” and the manufacturer or import..

The technical document Terminologies for Categorized Adverse Event Reporting (AER): Terms, Terminology and Codes has been updated by The International Medical Device Regulators Forum (IMDRF) Adverse Event Terminology working group (AET WG). The current update consists of 36 newly added terms, changes to 56 existing terms and the retirement of eight terms. Release notes that provide a high-level ..

The IVD expert panel has provided new scientific advice on SARS-CoV-2. The advice highlights that while the virus can still cause serious illness, it no longer poses a life-threatening risk with a significant mortality rate for the general European population.  This information may affect how SARS-CoV-2 tests are classified under Regulation (EU) 2017/746. Manufacturers are encouraged to assess h..

BackgroundThe Chief Executive, Dr. Muralitharan Paramasua, of the regulator in Malaysia, the Medical Device Authority (MDA), hosted the 2025 keynote address (January 14).Many programs were presented: e-labeling, UDI, import permit, guidance documents, Medcast 3.0, additional recognized ASEAN countries, and Class A fees. This update focuses on one of the global harmonization/regulatory reliance i..

The Medicines and Healthcare products Regulatory Agency (MHRA) announced the release of a suite of post-market surveillance (PMS) guidance (January 15) in alignment with The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024. BackgroundAs Emergo by UL reported last month, the amendment introduces new and enhanced PMS requirements for manufacturer..

Manufacturers applying to register a medical device or IVD with the Australian Register of Therapeutic Goods (ARTG) now have more options to leverage to fulfill the Manufacturer Evidence requirement to support an application. As a result, manufacturers may leverage their EU CE Marking Certificate issued under the IVDD to fulfill the Manufacturer Evidence requirement until the dates listed below...

식품의약품안전처에서 최근 정밀의료기술 발달로 종양 관련 체세포 유전자 변이를 검체 채취가 상대적으로 쉬운 액상검체 (혈장 등)에서 검사하여 치료제의 선택 또는 예후에 대한 정보를 제공하는 제품 개발이 증가함에 따라 관련 제품의 개발을 돕고 허가 심사에 참고하고자 '순환종양 DNA (Circulating Tumor DNA)를 분석하는 유전자 검사 제품의 액상검체 사용의 타당성 평가 시 고려사항'을 마련하였다. ▶ 세부내용검체 타당성 평가 시 고려사항  - 검체 유형 설정의 과학적 근거  - 검체의 채취 및 검사 전 절차에 관한 고려사항  - 성능 평가에 관한 고려사항  - 결과보고 및 해석에 관한 고려사항  민원인 안내서 > 민원설명회 자료 > 순환 종양 DNA(circulating tumor DNA)를 ..

식품의약품안전처에서 '체외진단의료기기 제조 및 품질관리기준' 일부개정고시 하였다. ▶ 개정이유품질관리 우수제조소의 경우 정기심사 시 제출서류를 간소화 등 개선하고, 품질시스템에 미치는 영향이 적고 발생 빈도가 적은 경미한 부적합의 경우 우선 판매 가능하도록 심사결과 판정기준 등을 정비하고자 함 ▶ 주요내용품질관리 우수제조소에 대한 적합성인정심사방법 개선품질에 미치는 영향 정도를 고려한 적합성인정 심사판정 개선 ▶ 부칙고시한 날로부터 시행다만, 제8조제6항, 제9항제1호, 제10조제5항 및 별표 2 9.4 제2호의 개정규정은 2025년 05월 01일부터 시행한다.  식품의약품안전처>법령/자료>법령정보>제개정고시등 - 상세보기 | 식품의약품안전처법령/자료>법령정보>제개정고시등 | 식품의약품안전처" data-..